Working… Menu

MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00373152
Recruitment Status : Withdrawn (No patient accrual)
First Posted : September 7, 2006
Last Update Posted : December 5, 2017
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

Brief Summary:

RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in learning how well radiofrequency ablation works to kill breast cancer cells and help doctors predict whether breast cancer cells remain after treatment.

PURPOSE: This phase II trial is studying how well MRI works in predicting tumor response after radiofrequency ablation in women with invasive breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Procedure: Lumpectomy Procedure: dynamic contrast-enhanced magnetic resonance imaging Procedure: radiofrequency ablation Radiation: gadopentetate dimeglumine Phase 2

Detailed Description:



  • Determine if radiofrequency ablation (RFA) can induce complete tumor necrosis in women with invasive breast cancer.


  • Determine whether breast MRI can accurately predict residual cancer and tumor necrosis in patients treated with RFA.
  • Determine the toxicity of RFA in these patients.
  • Determine the cosmetic outcome after RFA in these patients.

OUTLINE: This is a prospective, nonrandomized study.

Patients undergo dynamic contrast-enhanced MRI (DCE-MRI) using gadopentetate dimeglumine. Within the next few days, patients undergo radiofrequency ablation (RFA) over approximately 20-30 minutes. Patients then undergo a second DCE-MRI 3 to 21 days after RFA, followed by definitive surgery (standard mastectomy or lumpectomy).

Pathologic confirmation of the post-ablation DCE-MRI findings is performed within 1 to 21 days after the second MRI. Tumor cell viability and proliferative activity are assessed by immunohistochemical and biomarker analysis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Breast MRI Assessment of Tumor Viability After Radiofrequency Ablation (RFA)
Study Start Date : March 2005
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: RadioFrequency Ablation for Breast Cancer Procedure: Lumpectomy
Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.

Procedure: dynamic contrast-enhanced magnetic resonance imaging
Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
Other Name: MRI

Procedure: radiofrequency ablation
RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.

Radiation: gadopentetate dimeglumine
Injected at baseline MRI and post radiofrequency ablation MRI.
Other Names:
  • contrast dye
  • Gd-DTPA

Primary Outcome Measures :
  1. Complete Tumor Necrosis
    Efficacy of radiofrequency ablation (RFA) in inducing complete tumor necrosis as measured by immunohistochemical and biomarker studies.

Secondary Outcome Measures :
  1. Sensitivity and specificity of delayed dynamic contrast-enhanced MRI (DCE-MRI) in detecting residual cancer after RFA as measured by the Hylton method
  2. Cosmetic Outcome [ Time Frame: after RFA but before definitive surgery ]
    as rated by EORTC QLQ-C30. The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. The rating system includes evaluation of breast size and shape, skin tone, nipple shape and location, appearance of the surgical scar, and overall cosmetic results. With the exception of evaluation of the surgical scar, all ratings are based on a comparison of the treated breast with the untreated breast. Patients will also rate the cosmetic outcome as excellent-good-fair-poor.

  3. Toxicity or complications of RFA [ Time Frame: before definitive surgery ]

    as assessed by CTCAE v3.0 (Common Toxicity Criteria for Adverse Events, version 3.0).

    Any complications of RFA will be determined and documented before definitive surgery. Anticipated complications may include bleeding, pain, infection, and skin and chest muscle burns.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of invasive breast cancer - the following information must be known based on the needle core biopsy: tumor grade, hormone receptor status, and HER2/neu status. Patients with a previous history of either ipsilateral or contralateral excisional biopsy are not excluded. However, patients are excluded if an excisional biopsy was used to diagnose the current breast cancer.

Note: Subjects undergoing sentinel lymph node (SLN) biopsy will not be excluded from this research study. It is not expected that radiofrequency ablation (RFA) will interfere with the SLN procedure because other studies have demonstrated the accuracy of sentinel node staging after excisional biopsy. The axillary staging in these subjects will be noted.

  • Tumor size < 2 centimeters by mammogram or ultrasound, with ultrasound being the preferred method of evaluation. Measurements by physical exam should also be recorded. If mammogram and ultrasound are discordant, then the imaging modality that determines the largest tumor size will be used to determine eligibility.
  • Ultrasound measurements: Distance from tumor to skin must be > 1 cm; distance from tumor to chest wall must be > 1 cm. The RFA procedure, which burns the tumor, may also burn the skin or muscle if it is too close (< 1cm).
  • Laboratory values within 2 weeks of registration: platelet count ≥ 50,000; INR ≤ 1.6; serum creatinine ≤ 1.5 mg/dL; glomerular filtration rate (GFR) ≥ 60 ml/min/m^2
  • Age 18 years or older
  • Women must not be pregnant due to MR scanning of pregnant women is not FDA approved. All females of childbearing potential must have a urine study within 2 weeks prior to registration to rule out. Breast feeding must be discontinued prior to study entry.

Exclusion Criteria:

  • Subjects for whom neo-adjuvant therapy is planned will be excluded from this study
  • Patients with history of severe asthma and/or allergies will be excluded to avoid potential adverse reactions to the MRI contrast agent (Gd-DTPA)
  • Patients with pacemakers, any ferromagnetic implants or other ferromagnetic objects will be excluded
  • Patients with obesity (>250 pounds) will be excluded due to the limited diameter of the magnet bore tube
  • Patients with history of severe claustrophobia will be excluded

Patient must give written informed consent indicating the investigational nature of the study and its potential risks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00373152

Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Layout table for investigator information
Study Chair: Todd M. Tuttle, MD Masonic Cancer Center, University of Minnesota

Layout table for additonal information
Responsible Party: Masonic Cancer Center, University of Minnesota Identifier: NCT00373152     History of Changes
Other Study ID Numbers: 2005LS006
UMN-0412M66271 ( Other Identifier: IRB, University of Minnesota )
First Posted: September 7, 2006    Key Record Dates
Last Update Posted: December 5, 2017
Last Verified: December 2017
Keywords provided by Masonic Cancer Center, University of Minnesota:
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
stage IIIC breast cancer
stage IV breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases